Extracellular water-to-total body water ratio as an objective biomarker for frailty in lung cancer patients

7Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Our previous study revealed the association between extracellular water-to-total body water ratio (ECW/TBW) and the therapeutic durability of chemotherapy and/or immune checkpoint inhibitors in advanced lung cancer. We retrospectively examined the usefulness of ECW/TBW in detecting frailty compared to other bioelectrical impedance (BIA) parameters in a larger number of patients. Patients and Methods: Lung cancer patients underwent BIA before anti-cancer therapy at our hospital between June 1, 2018 and July 31, 2020. Results: Of 99 patients, 26 were assigned to ECW/TBW≥0.4 (higher group: HG) and 57 to ECW/TBW<0.4 (lower group: LG). ECW/TBW increased significantly with performance deterioration and ageing. HG patients had significantly shorter time-to-treatment failure (TTF) than LG patients. In patients with performance status 0-1, those in the HG had shorter TTF than those in the LG. ECW/TBW was the only independent predictor of TTF according to multivariate analysis. Conclusion: ECW/TBW is an objective biomarker for detecting frailty among lung cancer patients.

Cite

CITATION STYLE

APA

Hirashima, T., Noda, Y., Suzuki, H., Nasu, S., Tanaka, A., Morishita, N., … Okamoto, N. (2021). Extracellular water-to-total body water ratio as an objective biomarker for frailty in lung cancer patients. Anticancer Research, 41(3), 1655–1662. https://doi.org/10.21873/anticanres.14928

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free